#1
|
|||
|
|||
Пояснения wanted
П-те п-та... :-(
Accrual to the study has been slow as the study mandated that patients may not have received prior oxal; the first patient to start treatment was on 19 March 2003 and the last was on 16 January 2008. For this reason, there is a long median follow-up of 43 months. One-year survival was 100%, 2-year survival 97% and 3-, 4- and 5-year survival 88% (Figure 1). Median survival has not been reached. И шо це значить? Зато про выживаемость без прогрессирования - есть. he median PFS is 37.7 months (95% CI 16.5 to infinity). |